Last updated on November 2017

Type II Diabetic Patients at High Risk For Cardiovascular Events

Brief description of study

Type II Diabetic Patients at High Risk For Cardiovascular Events

Detailed Study Description

Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes

Inclusion Criteria:

  • Provision of informed consent prior to any study specific procedures
  • Female or male aged ≥40 years
  • Diagnosed with Type 2 Diabetes
  • High Risk for Cardiovascular events

Exclusion Criteria:

  • Diagnosis of Type 1 diabetes mellitus History of bladder cancer or history of radiation therapy to the lower abdomen or pelvis at any time
  • Chronic cystitis and/or recurrent urinary tract infections
  • Pregnant or breast-feeding patients

Please note: Other protocol specific Inclusion/Exclusion Criteria apply. Compensation for time and travel will be provided for each completed visit.

Clinical Study Identifier: TX13511


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Lauraine Crandall

Cardiology Research Associates
Daytona Beach, FL USA
  Connect »